Organizations Filed Purposes:
THE SPECIFIC AND PRIMARY PURPOSE AND CHARITABLE MISSION OF GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES IS TO CONDUCT RESEARCH ON AND DEVELOP VACCINES AND DIAGNOSTICS FOR LIFE-THREATENING INFECTIOUS DISEASES, INCLUDING HIV. GSID IS ALSO COMMITTED TO PROVIDE ASSISTANCE TO AND COLLABORATE WITH OTHER GLOBAL PUBLIC HEALTH ORGANIZATIONS, PRIVATE FOUNDATIONS, AND FOR-PROFIT ENTITIES FOCUSED ON PUBLIC HEALTH ISSUES, FOR THE PURPOSE OF FACILITATING ACCESS TO AFFORDABLE HEALTH SOLUTIONS WHICH BENEFIT THE PEOPLE IN DEVELOPING COUNTRIES, WHO ARE THE MOST IN NEED.
the mission of GSID is to expand the development of low-cost effective tools for the diagnosis and prevention of infectious diseases afflicting less developed countries.
AIDSVAX HIV VACCINE PROGRAM: GSIDs only program service area in 2019 was serving as manufacturing and product sponsor for its AIDSVAX vaccine and maintaining an HIV specimen and manufacturing reagents repository. During 2019, GSID negotiated collaboration agreements and began planning for a Phase IIb efficacy trial in four Sub-Saharan countries in Africa. Funding for GSIDs activities in 2019 was solely provided by the Henry M. Jackson Foundation (Bethesda, MD). Funding in 2020 will also be provided by Imperial College of London, the sponsor of the trial in southern Arica. Some planning activities related to this program were conducted by GSID personnel on the ground in Sub-Saharan Africa during 2019. GSID established a repository containing the serological specimens collected during the VAX003 phase III clinical trial conducted in Thailand. The specimens are provided under material transfer agreement to investigators in the scientific community who are working towards finding a better understanding of the virus that causes AIDS and to those scientists who are developing vaccines to prevent HIV infection. The repository also contains other materials such as: GMP-grade vaccine, manufacturing reagents, research-grade vaccine and data which are also provided to the research community to conduct experiments, pre-clinical trials and human clinical trials; and to develop laboratory assays. In September 2018, the materials repository was relocated to a biopharmaceutical storage facility in Frederick, Maryland.
Diagnostics & Surveillance Program: GSID is developing a system to rapidly diagnose and report the occurrence of infectious diseases in low resource point-of-care settings. The intent is to assist the healthcare provider by obtaining an accurate diagnosis so that the appropriate treatment is initiated quickly and information is communicated to governmental agencies and NGOs that formulate public health policy and allocate resources. In 2019, no GSID personal conducted activities on the ground in Zimbabwe and Mozambique.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Carter A Lee | Executive Director | 32 | $170,500 |
| Vineeta G Gulati | DIRECTOR, CLINICAL OPS & REG | 32 | $144,700 |
| Keith W Higgins | PROG COOR & REPOSITORY MGR | 32 | $125,500 |
| Faruk M Sinangil | Board Member | 20 | $90,700 |
| Dr Seung-Il Shin | Board Member | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202011889349302051_public.xml